Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AR342
- Development stage
- Unknown
- Lead developer
- Anshi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AR342 is a small molecule therapeutic candidate being developed by Anshi Pharmaceutical (Zhongshan) Inc. for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). The drug is currently in Phase 1 clinical development. While it is a key part of Anshi's metabolic disease pipeline, specific details regarding its biological target, mechanism of action, and chemical structure have not been publicly disclosed by the developer. Anshi Pharmaceutical is a China-based company focused on developing novel treatments for chronic conditions, including metabolic and inflammatory diseases.
Beyond the preview
Go deeper on AR342.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AR342.